Harpoon Therapeutics, Inc.
Total raised
$220 M
4 rounds on record
Latest round
$100 M
Oct 2023
First round on record
May 2017
Today
Private
No later event on record
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Harpoon Therapeutics, Inc. had revenue between $5 million and $25 million when it filed its newest notice of a funding round (Oct 2023).
SEC Form D (revenue range) · Oct 2023
The industry group it chose in its notices: Biotechnology.
SEC Form D · Oct 2023
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
18 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Arix Bioscience Holdings Ltd | Company | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Arix Bioscience PLC | Company | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| MPM Asset Management Investors BV2014 LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| MPM Asset Management LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| MPM Bioimpact LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| MPM BioVentures 2014 (B), L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| MPM BioVentures 2014 GP LLC | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| MPM BioVentures 2014 LLC | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| MPM BioVentures 2014, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| MPM Oncology Impact Management GP LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| New Leaf Biopharma Opportunities II, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| New Leaf BPO Associates II, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| New Leaf BPO Management II, L.L.C | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| New Leaf Venture Associates III, L.P. | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| New Leaf Venture Management III, L.L.C. | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| New Leaf Ventures III, L.P. | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| Oncology Impact Fund (Cayman) Management L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| UBS Oncology Impact Fund L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Julie Eastland | Executive officer | Oct 2023 |
| Luke Walker | Executive officer | Oct 2023 |
| Luke Nathaniel Walker | Executive officer | Apr 2023 |
| Georgia L. Erbez | Chief Financial Officer | Nov 2018 |
| Gerald McMahon | President and CEO | Nov 2018 |
| Holger R. Wesche | Chief Scientific Officer | Nov 2018 |
| Natalie R. Sacks | Chief Medical Officer | Nov 2018 |
| William E. Picht | Executive officer | Jun 2017 |
| Andrew Robbins | Director | Oct 2023 |
| Jonathan Drachman | Director | Oct 2023 |
| Joseph Bailes | Director | Oct 2023 |
| Julie Eastland | Director | Oct 2023 |
| Lauren Silvernail | Director | Oct 2023 |
| Mark Chin | Director | Oct 2023 |
| Ronald Hunt | Director | Oct 2023 |
| Scott Myers | Director | Oct 2023 |
| Alan Colowick | Director | Apr 2023 |
| Joanne P. Viney | Director | Apr 2023 |
| Lauren P. Silvernail | Director | Apr 2023 |
| Gerald McMahon | President and CEO | Nov 2018 |
| Jonathan R. Drachman | Director | Nov 2018 |
| Julie R. Eastland | Director | Nov 2018 |
| Luke R. Evnin | Director | Nov 2018 |
| Mark R. Chin | Director | Nov 2018 |
| Patrick R. Baeuerle | Director | Nov 2018 |
| Ron R. Hunt | Director | Nov 2018 |
| Scott R. Myers | Director | Nov 2018 |
| Dan E. Hicklin | Director | Jun 2017 |
| Luke E. Evnin | Director | Jun 2017 |
| Mark E. Chin | Director | Jun 2017 |
| Pablo E. Cagnoni | Director | Jun 2017 |
| Patrick E. Baeuerle | Director | Jun 2017 |
| Ron E. Hunt | Director | Jun 2017 |